AB Science (STU:A8D) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:A8D AB Science STU:A8D
52 GF Score
Price €0.61
GF Value €1.28
Valuation Possible Value Trap
! 11 Warning Signs
View Full Analysis

What is AB Science Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:A8D
52GF Score
AB Science STU:A8D
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AB Science (STU:A8D) Overvalued in 2026?

Based on GuruFocus' analysis, AB Science stock appears to be undervalued. The current stock price of €0.61 is trading 52.3% below its estimated GF Value™ of €1.28. GuruFocus considers AB Science to be Possible Value Trap.

Key valuation signals for STU:A8D:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €1.28 vs. price of €0.61 (52.3% below fair value)
  • GF Score™: 52/100 with 11 warning signs

No single metric tells the full story. See the STU:A8D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AB Science Business Description

Other Exchanges ABSCF:USA0Q77:UKAB:France
Address 3, Avenue George V, Paris, FRA, 75008
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
52GF Score

Get the complete analysis for STU:A8D

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.61
Price
€1.28
GF Value